eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Special issues Abstracting and indexing Subscription
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2009
vol. 5
 
Share:
Share:

LETTER TO EDITOR
Biochemical diagnosis of pheochromocytoma

Emilia Boczek-Leszczyk
,
Konrad Szosland

Arch Med Sci 2009; 5, 1: 120-121
Online publish date: 2009/04/22
Article file
- biochemical.pdf  [0.05 MB]
Get citation
 
 
Recommendations from the First International Symposium on Pheochromocytoma, held in October 2005, indicate that among biochemical tests useful for diagnosis of pheochromocytoma the first-line test should be measurement of plasma or urinary fractionated metanephrines [1]. Previous results show that these biochemical tests are connected with higher specificity and sensitivity compared with others [2]. According to various studies, the sensitivity was from 95 to 100% for fractionated plasma metanephrines and from 90 to 97% for fractionated urinary metanephrines. The specificity was also quite good, ranging from 85 to 95% for fractionated plasma metanephrines and from 69 to 99% for fractionated urinary metanephrines [3-6]. Measurement of fractionated plasma metanephrines should be preferred especially in patients with familial endocrine syndromes [4]. Moreover, in the case of sporadic tumour diagnostic efficacy of fractionated plasma metanephrines measurement alone is the same as measurement of total concentration of metanephrines and fractionated catecholamines in urine at the same time [4]. Plasma fractionated metanephrine levels within the normal range exclude the presence of pheochromocytoma. On the other hand, diagnosis of pheochromocytoma based on increased concentrations of plasma fractionated metanephrines does not need to be confirmed with additional biochemical tests (in 80% of cases) [7]. This test allows one to predict size of tumour and location (adrenal gland or behind it) [5]. In the case of a choice of one of the metanephrines (metanephrine or normetanephrine) measurement of plasma normetanephrine is recommended as the best single biochemical test [3, 5, 6].

References

1. Pacak K, Eisenhofer G, Ahlman H, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab 2007; 3: 92-102.
2. Szosland K, Kopff B, Lewiński A. Pheochromocytoma – chromaffin cell tumor [Polish]. Pol J Endocrinol 2006; 1: 54-62.
3. Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002; 287: 1427-34.
4. Sawka AM, Jaeschke R, Singh RJ, Young WF Jr. A comparison of biochemical test for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 2003; 88: 553-8.
5. Eisenhofer G, Lenders JW, Goldstein DS, et al. Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin Chem 2005; 51: 735-44.
6. Unger N, Pitt C, Schmidt IL, et al. Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass. Eur J Endocrinol 2006; 154: 409-17.
7. Goldstein DS, Eisenhofer G, Flynn JA, Wand G, Pacak K. Diagnosis and localization of pheochromocytoma. Hypertension 2004; 43: 907-10.
Copyright: © 2009 Termedia & Banach. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.